article Open AccessTop 10% cited

Ki67, chemotherapy response, and prognosis in breast cancer patients receiving neoadjuvant treatment

BMC Cancer · 2011 · Vol. 11(1) · pp. 486–486

Peter A. Fasching✉(University of California, Los Angeles)Katharina Heusinger(Universitätsklinikum Erlangen)Lothar Haeberle(Universitätsklinikum Erlangen)Melitta Niklos(Universitätsklinikum Erlangen)Alexander Hein(Universitätsklinikum Erlangen)Christian Bayer(Universitätsklinikum Erlangen)Claudia Rauh(Universitätsklinikum Erlangen)R. Schulz-Wendtland(Universitätsklinikum Erlangen)Mayada R. Bani(Universitätsklinikum Erlangen)Michael Schrauder(Universitätsklinikum Erlangen)Laura Kahmann(Universitätsklinikum Erlangen)Michael P. Lux(Universitätsklinikum Erlangen)Johanna Strehl(Friedrich-Alexander-Universität Erlangen-Nürnberg)Arndt Hartmann(Universitätsklinikum Erlangen)Arno Dimmler(St. Vincentius-Kliniken)Matthias W. Beckmann(Universitätsklinikum Erlangen)David L. Wachter(Friedrich-Alexander-Universität Erlangen-Nürnberg)

View via DOI Full-text PDF

Abstract

Ki67 has predictive and prognostic value and is a feasible marker for clinical practice. It independently improved the prediction of treatment response and prognosis in a group of breast cancer patients receiving neoadjuvant treatment. As mean Ki67 values in patients with a pCR were very high, cut-off values in a high range above which the prognosis may be better than in patients with lower Ki67 values may be hypothesized. Larger studies will be needed in order to investigate these findings further.

Breast Cancer Treatment Studies Cancer Genomics and Diagnostics HER2/EGFR in Cancer ResearchMedicineBreast cancerInternal medicineOncologySurgical oncologyGrading (engineering)ChemotherapyNeoadjuvant therapyEstrogen receptorPathological

MeSH terms

HumansAdultAgedAntineoplastic AgentsBreast NeoplasmsFemaleImmunohistochemistryMiddle AgedPredictive Value of TestsPrognosisRetrospective StudiesBiomarkers, TumorSurvival RateProportional Hazards ModelsChemotherapy, Adjuvant